肝肾综合征
Hepatorenal syndrome.
作者信息
Ng Charles K F, Chan Michael H M, Tai Morris H L, Lam Christopher W K
机构信息
Department of Chemical Pathology, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong.
出版信息
Clin Biochem Rev. 2007 Feb;28(1):11-7.
Abstract
Hepatorenal syndrome (HRS) is a serious complication of liver cirrhosis with critically poor prognosis. The pathophysiological hallmark is severe renal vasoconstriction, resulting from complex changes in splanchnic and general circulations as well as systemic and renal vasoconstrictors and vasodilators. Rapid diagnosis and management are important, since recent treatment modalities including vasoconstrictor therapy can improve short-term outcome and buy time for liver transplantation, which can result in complete recovery.
摘要
肝肾综合征（HRS）是肝硬化的一种严重并发症，预后极差。其病理生理特征是严重的肾血管收缩，这是由内脏和全身循环以及全身和肾血管收缩剂与血管扩张剂的复杂变化所致。快速诊断和治疗很重要，因为包括血管收缩剂治疗在内的最新治疗方式可改善短期预后，并为肝移植争取时间，而肝移植可使患者完全康复。
相似文献
1
Hepatorenal syndrome.
Clin Biochem Rev. 2007 Feb;28(1):11-7.
2
Current therapies in hepatorenal syndrome.
Rom J Intern Med. 2014 Oct-Dec;52(4):201-15.
3
Vasoconstrictor therapy for hepatorenal syndrome in liver cirrhosis.
Curr Pharm Des. 2006;12(35):4637-47. doi: 10.2174/138161206779010413.
4
Hepatorenal Syndrome.
Clin J Am Soc Nephrol. 2019 May 7;14(5):774-781. doi: 10.2215/CJN.12451018. Epub 2019 Apr 17.
5
Recent advances in our understanding of hepatorenal syndrome.
Nat Rev Gastroenterol Hepatol. 2012 May 22;9(7):382-91. doi: 10.1038/nrgastro.2012.96.
6
[Hepatorenal syndrome].
Nephrol Ther. 2014 Feb;10(1):61-8. doi: 10.1016/j.nephro.2013.11.005. Epub 2014 Jan 1.
7
Hepatorenal syndrome.
Forum (Genova). 1998 Jan-Mar;8(1):62-81.
8
Hepatorenal syndrome.
World J Gastroenterol. 2007 Aug 14;13(30):4046-55. doi: 10.3748/wjg.v13.i30.4046.
9
[Hepatorenal syndrome].
Srp Arh Celok Lek. 2007 Jan-Feb;135(1-2):98-104.
10
Hepatorenal syndrome.
Dig Dis. 2005;23(1):47-55. doi: 10.1159/000084725.
引用本文的文献
1
Role of oral Midodrine in preventing hepatorenal syndrome in Child-Turcotte-Pugh class C cirrhotics: a pilot study.
Gastroenterol Hepatol Bed Bench. 2024;17(4):438-449. doi: 10.22037/ghfbb.v17i4.3019.
2
Timing and Indications for Liver Transplantation for Children with Chronic Liver Disease.
Children (Basel). 2025 Mar 31;12(4):449. doi: 10.3390/children12040449.
3
The unexpected diagnosis of karyomegalic interstitial nephritis in a presumed case of Mesoamerican Nephropathy: a case report.
Front Med (Lausanne). 2025 Mar 5;12:1465783. doi: 10.3389/fmed.2025.1465783. eCollection 2025.
4
Update on the Complications and Management of Liver Cirrhosis.
Med Sci (Basel). 2025 Feb 5;13(1):13. doi: 10.3390/medsci13010013.
5
A Study of the Clinical Profiles of Patients With Hepatorenal Syndrome.
Cureus. 2024 Aug 13;16(8):e66778. doi: 10.7759/cureus.66778. eCollection 2024 Aug.
6
ALBI Grade Is Associated with Clinical Outcomes of Critically Ill Patients with AKI: A Cohort Study with Cox Regression and Propensity Score Matching.
Mediators Inflamm. 2024 Jul 18;2024:1412709. doi: 10.1155/2024/1412709. eCollection 2024.
7
A hospitalist's approach to managing acute kidney injury (hepatorenal syndrome) in cirrhosis.
Clin Liver Dis (Hoboken). 2024 Apr 26;23(1):e0159. doi: 10.1097/CLD.0000000000000159. eCollection 2024 Jan-Jun.
8
Role of albumin infusion in cirrhosis-associated complications.
Clin Exp Med. 2024 Mar 29;24(1):58. doi: 10.1007/s10238-024-01315-1.
9
VWF/ADAMTS13 Ratio as a Potential Predictive Biomarker for Acute Kidney Injury Onset in Cirrhosis.
Dig Dis Sci. 2024 Mar;69(3):851-869. doi: 10.1007/s10620-023-08257-w. Epub 2024 Jan 20.
10
INFUSE: Rationale and design of a multi-center, open label, collaborative study to treat HRS-AKI with continuous terlipressin infusion.
Contemp Clin Trials Commun. 2023 Oct 5;36:101211. doi: 10.1016/j.conctc.2023.101211. eCollection 2023 Dec.
本文引用的文献
1
LIVER TRAUMA AND THE HEPATORENAL SYNDROME.
Ann Surg. 1939 Oct;110(4):682-92. doi: 10.1097/00000658-193910000-00015.
2
Pathophysiological basis of pharmacotherapy in the hepatorenal syndrome.
Scand J Gastroenterol. 2005 May;40(5):491-500. doi: 10.1080/00365520510012064.
3
Circulatory function and hepatorenal syndrome in cirrhosis.
Hepatology. 2005 Aug;42(2):439-47. doi: 10.1002/hep.20766.
4
Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome.
Hepatology. 2004 Jul;40(1):55-64. doi: 10.1002/hep.20262.
5
Endothelin and vascular function in liver disease.
Gut. 2004 Feb;53(2):159-61. doi: 10.1136/gut.2003.024703.
6
Effects of treatment of hepatorenal syndrome before transplantation on posttransplantation outcome. A case-control study.
J Hepatol. 2004 Jan;40(1):140-6. doi: 10.1016/j.jhep.2003.09.019.
7
Electrolyte and circulatory changes in terminal liver failure.
Lancet. 1956 Dec 1;271(6953):1121-5. doi: 10.1016/s0140-6736(56)90149-0.
8
Transjugular intrahepatic portosystemic shunt: current status.
Gastroenterology. 2003 May;124(6):1700-10. doi: 10.1016/s0016-5085(03)00377-9.
9
Beneficial effects of terlipressin in hepatorenal syndrome: a prospective, randomized placebo-controlled clinical trial.
J Gastroenterol Hepatol. 2003 Feb;18(2):152-6. doi: 10.1046/j.1440-1746.2003.02934.x.
10
Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study.
Hepatology. 2002 Oct;36(4 Pt 1):941-8. doi: 10.1053/jhep.2002.35819.
Zotero 插件